Search
AstraZeneca China Undergoes Organizational Restructuring
2 week ago /
Read about 0 minute
Author：小编
AstraZeneca China has announced the implementation of structural adjustments effective July 1, creating two key divisions: the Gastrointestinal Oncology Business Unit and the Early Pipeline Business Unit. This move aims to catalyze strategic transformation and expedite the development pipeline, ultimately offering patients a broader range of treatment options.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
